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Background: Sinonasal undifferentiated carcinoma (SNUC) is a rare malignancy with often dismal outcomes. This
study set to determine provincial and literature-wide survival outcomes based on treatment modality.
Methods: Retrospective chart review of all SNUC patients in the province of Alberta from 1986–2010 was
conducted. A review of the literature of SNUC patients was also performed. Patient/tumor characteristics, treatment,
and follow-up/survival data were collected. Kaplan-Meier and Cox regression survival analyses were performed.
Results: 20 patients were treated for SNUC in Alberta and 140 patients were identified in the literature. Pooled
median disease-free survival was 12. 7 months and 5-year survival estimate was 6.25%. Cox-Regression analysis
demonstrated an overall survival advantage with multimodality treatments (Log-Rank test: p = 0.015). However, no
statistically significant differences in disease-free and overall survival were identified between patients treated with
chemoradiation or surgery followed by adjuvant therapy.
Conclusions: Treatment of SNUC remains challenging with poor survival outcomes. There appears to be no
statistically significant difference in overall, or disease-free survival between treatment modalities.Introduction
Sinonasal undifferentiated carcinoma (SNUC) is a rare,
highly aggressive and clinico-pathologically distinctive
carcinoma of uncertain histogenesis [1]. The disease
affects males more often than females and has a broad
age range [2]. SNUC presents as a rapidly enlarging
tumour arising from the sinonasal tract with initially
vague symptoms [3] that are of relatively short duration.
Orbital, dural, and intracranial invasion are common
[2,4] at presentation.
Pathological examination of SNUC typically reveals
large tumours with fungating and poorly defined margins
that invade adjacent structures [1]. The histologic appear-
ance is characterized by sheets, trabecular, and ribbon-like
arrangements of small to medium-size undifferentiated
cells. These cells often have high nuclear to cytoplasmic
ratio, high mitotic rate, and prominent tumour necrosis
[3]. Lymphovascular and neural invasion are often also
identified [3]. Immuno-histochemical antigenic profiles* Correspondence: caroline.xu@ualberta.ca
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reproduction in any medium, provided the orvary widely [3], however, features of neuroectodermal dif-
ferentiation are typically absent [5].
The majority of patients present with advanced stage
disease and often undergo intense, multi-modality treat-
ment [6]. Unfortunately, survival remains poor [1,2,7,8].
The purpose of this study was to evaluate survival out-
comes based on treatment of SNUC patients in Alberta
and the literature at large.
Methods
Ethics approval was granted by the University of Alberta
Health Research Ethics Board (HREB) committee as well
as the Alberta Cancer Board. The study was conducted
at a tertiary care academic referral centre.
Provincial chart review
A systematic, retrospective medical record review was
performed. All patients diagnosed with SNUC in the
province of Alberta from 1986–2010 were identified in
the Alberta Cancer Registry [9], which is a certified
member of the North American Association for Central
Cancer Registries. Charts and electronic medical records
for all identified patients were then accessed and cross-
referenced to confirm suspected diagnoses of SNUC.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bank and analyzed by a single head and neck pathologist
(WTM). Any tumors with questionable pathology reports
were also obtained and analyzed. The following criteria
were then applied to these patients:
Inclusion Criteria:
1) Histological diagnosis of SNUC




Medical records were then gleaned for: patient, tumor
and treatment characteristics as well as follow-up time,
survival status, and disease-free status as of March 30th,
2010. Patient age was recorded as the age on the first
day of primary treatment. Clinical TNM staging was
obtained from multi-disciplinary tumor board notes,
which followed the American Joint Committee on Cancer
guidelines [10]. Overall survival was defined as the time
from the first day of treatment to death. Disease-free
survival was defined as the first day of treatment to disease
recurrence.
Literature review
A literature review was undertaken in a systematic fashion
using: MEDLINE, EMBASE, Pubmed, and Scopus. The
goal was to identify papers describing the survival of
SNUC as per treatment modality. Three reviewers
searched for the following terms: “sinonasal undifferenti-
ated carcinoma”, “SNUC”, “undifferentiated carcinoma”,
and “paranasal sinuses”. Foreign language studies were
included in the search strategy and only excluded from
the review if an English translation was not available. Bib-
liographies were also checked for relevant publications.
Abstracts of publications were screened for possible inclu-
sion (as per above criteria) and relevant articles were
reviewed in full. Studies were excluded if survival time and
status at last follow-up were not provided. Each study was
evaluated for gender and age of the patient in the study,
presenting symptoms, orbital involvement, treatment
strategy, and follow-up. Where AJCC staging was not pro-
vided, the Kadish staging was converted to an AJCC TMN
stage based on information provided.
Statistical analysis
Actuarial survival for pooled patients was estimated via
Kaplan-Meier analysis to account for censored data. A log
rank test was used to compare survival curves with statis-
tical significance set as p<0.05. Cox-regression analysiswas also performed. Covariate factors known to influence
survival including age, gender and tumor stage were incor-
porated as potential confounding variables. Statistical
analysis was conducted using SPSS 19.0 (SPSS Inc.,
Chicago, IL).
Results
20 histologically confirmed cases of SNUC were identi-
fied in Alberta. The majority of patients were male, mid-
dle-aged, and presenting with Stage IV disease (Table 1).
Patients presented with headache or neurologic symp-
toms (45%), nasal obstruction (40%), epistaxis (25%) and
occasionally, facial pain (5%). In many patients, the exact
tumour origin within the sinonasal tract was difficult to
determine due to the extensive nature of their tumours
on pre-operative imaging.
Systematic review and pooled analysis
42 potential articles were identified through a systematic
and comprehensive search. 26 articles met study criteria
and yielded 140 patients available for survival analysis
(Table 2). Patients in the literature presented with symp-
toms of nasal obstruction (20.0%), epistaxis (17.1%), diplo-
pia or other visual symptoms (15.0%), or headache (12.1%).
Rarely, patients also presented with facial pain (7.1%) or
sinusitis (2.9%). At presentation, 42.9% of patients had
orbital involvement. AJCC TNM staging was available for
128 (87.6%) of the patients with the majority comprising of
Stage IV disease (Table 2).
The majority of patients in the literature (66.4%) received
multimodality therapy (Table 3). Where recurrence data
was available (107 patients), the recurrence rate was 42.3%
with time to recurrence ranging from 3–33 months. 32.1%
of patients died of local disease while 14.3% of patients died
of metastatic disease. The most common sites of metastasis
were bone (10.2%), cervical lymph node (9.5%), lung (5.8%),
brain (5.8%), and liver (4.4%). The pooled median disease-
free survival was 12.7 months. The 1, 3 and 5-year survival
estimates were 51.2%, 19.4% and 6.25% respectively. The
median overall survival was 12.7 months.
Only two patients in Alberta received no treatment
(Table 3): one died days after presenting with a brain
abscess and another patient opted for no treatment. The
remainder of patients received either a single or multi-
modality approach. In nine of the 20 patients, metastasis
was detected within an average of 12.7 months (standard
deviation of 33.2 months, range: 2.6 months to 3.7 years).
The mean time from recurrence to death was 4.9 months
(standard deviation of 3.2 months, range: 1.0 to 7.8 months).
Seventeen patients (85%) died of their disease while the
remaining patients died of respiratory failure and/or aspi-
ration pneumonia.
A statistical difference in overall survival of pooled
patients was found between patients treated with single
Table 1 Baseline variables of SNUC patients in Alberta




Mean age at diagnosis, years (range) 53.9 (35–85)
Mean follow-up time, months 21
Stage at presentation Stage IV 17 (85)
Stage III 2 (10)
Stage II 1 (5)
Tumor origin site Sinonasal – not otherwise specified 7 (35)
Nasal cavity 4 (20)
Maxillary sinus 4 (20)
Ethmoid sinus 5 (25)
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did not translate to a difference in disease-free survival
(Figure 2). There were no differences in overall and
disease-free survival based on initial treatment, with Cox
regression analysis to account for covariables such as age,
sex, and stage (Figures 3 and 4).
Discussion
Rare sinonasal tumours are challenging clinical entities for
head and neck oncology and skull base surgeons [11-13].
Sinonasal undifferentiated carcinoma is a particularly diffi-
cult to treat.
We described the results of a series of 20 patients with
SNUC treated between 1986 and 2010 in Alberta. As con-
sistent with previous studies [4,14-19], the majority of
these patients presented with locally advanced disease. At
the senior author’s institution, patients with resectable
tumours are offered surgery followed by chemoradiation.
Chemotherapy agents used included carboplatin, cisplatin,
and etoposide. Surgical resection typically involved exten-
sive craniofacial resection with maxillectomy, orbital exen-
teration, and occasionally, neurosurgical involvement.Table 2 Patient demographics of SNUC patients in the
literature




Mean age, years (range) 52.5 (8-84)
TNM Stage Stage IV 102 (72.9)
Stage III 15 (10.7)
Stage II 11 (7.9)
Not Stated 12 (12.4)
Mean follow-up time, months 22Overall, outcomes of these patients were typical of those
depicted in the literature: patients had high rates of recur-
rence, metastatic disease, and had very limited disease-free
survival.
Kramer et al. [15] presented a case series and systematic
review of 60 patients with SNUC in the literature in 2004.
More recently, Reiersen et al. also presented a systematic
review of patients in the literature [20]. Their study had
similar findings of overall poor prognosis. However, the
study authors proposed that treatment of SNUC patients
should include surgery with adjuvant therapy. This is
based on findings that surgery was the best initial modality
and the addition of chemotherapy and radiation provided
additional survival benefits. Our results also suggest that a
multi-modality approach confers an overall survival ad-
vantage. However, our results failed to show a significant
advantage of surgical-based treatment stategies and there
appears to be no clear disease-free survival advantage with
any particular modality, based on our results.
Our study has several limitations. First, this is a review
and pooled analysis of an area of the literature comprised
entirely of small to medium-sized case series. The data is
heterogeneous and the quality is often poor. AJCC staging
information was not available for all patients and often the
Kadish staging system was necessarily converted to an
AJCC stage based on available information regarding ana-
tomic involvement. Firm conclusions are difficult to makeTable 3 Treatments received by SNUC patients
Modality Number of patients (%)
Alberta Literature
No treatment 2 (10) 5 (4)
Single modality 7 (35) 42 (30)
Chemoradiation 4 (20) 37 (26)
Surgery + Adjuvant radiotherapy 3 (15) 22 (16)
Surgery + Chemoradiation 4 (20) 34 (24)
Figure 1 Kaplan-Meir plot depicting overall survival by treatment modality.
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heterogeneity of clinical characteristics and treatment mo-
dalities. However, this study confirms that despite ad-
vances in chemotherapy and radiotherapy, the cure-rate
for SNUC remains dismally low. Recurrence rate is veryFigure 2 Kaplan-Meir plot depicting disease-free survival by treatmenhigh and many patients died of disease within months of
diagnosis.
Given the challenges and limited success in the treatment
of SNUC, alternative therapeutic modalities are clearly
necessary. Novel therapies that have been attemptedt modality.
Figure 3 Kaplan-Meir plot depicting overall survival by single versus multi-modality approaches.
Figure 4 Kaplan-Meir plot depicting disease-free survival by single versus multi-modality approaches.
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bone marrow transplant [22], and neoadjuvant selective
intra-arterial cisplatin with concurrent radiation therapy
[23], both of which showed limited success. A recent histo-
biochemical study of a small series of SNUC patients
showed that these tumours have a strong expression c-KIT,
which is a tyrosine kinase receptor typically expressed in
gastrointestinal stromal tumours [24]. However, over-
expression was not due to an activating mutation in the
c-kit gene, and thus, the authors argued that use of TK-
inhibitors targeting c-KIT (e.g. Imatinib/Gleevac) may not
prove successful. However, this represents a possible new
avenue of therapy.
Conclusions
SNUC is a unique clinico-pathologic entity that remains a
challenge to treat despite aggressive multidisciplinary
approaches. There is no evidence that aggressive surgery
and post-operative RT offer any survival advantage com-
pared to other modalities. Therefore, a search for alterna-
tive therapies is warranted.
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